Research progress in population pharmacokinetics of voriconazole in adults

doi:10.12092/j.issn.1009-2501.2019.09.009

Abstract

Abstract:

AIM: Voriconazole has strong antifungal activity and broad antifungal spectrum, but its pharmacokinetics is highly variable due to various factors. In this paper, the pharmacokinetic characteristics of voriconazole were described based on the population pharmacokinetic model, which provided a theoretical basis for the individualized use of voriconazole. METHODS: The pharmacokinetics of voriconazole was characterized by searching the literatures of voriconazole population pharmacokinetics in CNKI, Pubmed and Web of Science. RESULTS:Nine studies reported the PPK model of voriconazole was one-compartment models and 4 studies were two-compartment models. The main influencing factors of voriconazole pharmacokinetics were age, body weight, CY2C19 phenotype, liver function and concomitant medication. CONCLUSION: There is considerable variation between voriconazole individuals. For specific populations, it is especially important to develop a personalized dosing regimen.

Key words: voriconazole, pharmacokinetics, population pharmacokinetics, influencing factors

CLC Number:

R969.1

LIU Simin, CAI Jun, LI Huixin, YANG Li, ZHAO Yan, ZHANG Jinping. Research progress in population pharmacokinetics of voriconazole in adults[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1015-1023.

References

［1］Gegorge D, Miniter P, Andriole VT. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis［J］. Antimicrob Agents Chemother,1996,40:86-91.
［2］Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis［J］. Clin Infect Dis, 2002, 34(5):563-571.
［3］Miyakis S, Van Hal SJ, Solvag CJS, et al. Clinician ordering practices for voriconazole therapeutic drug monitoring: Experiences of a referral laboratory［J］. Ther Drug Monit, 2010, 32(5):661-664.
［4］余静洁,杨四涛,周星,等.基于伏立康唑血药浓度监测成功干预药物相互作用3例［J］.医药导报,2017，36(8):879-883.
［5］张寒娟,谢悦旭,任彤,等.根据治疗药物监测指导伏立康唑个体化用药的案例分析［J］.药学服务与研究, 2019,19(2):129-132.
［6］Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole［J］. Drug Metab Dispos,2003,31:540-547.
［7］US Food and Drug Administration. Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review: voriconazole (Vfend)［R/OL］ . ( 2019-08-19 ) https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021464s000_021466s000_Vfend_biopharmr.pdf
［8］Michael JD, Gerd M, Johanna W,et al. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing［J］. J Antimicrob Chemother, 2014,69:1633-1641.
［9］Liu P, Diane RM. Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis［J］. Antimicrob Agents Chemother, 2014,58(8):4718-4726.
［10］Wang TT, Chen SY, Sun JY, et al.Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungalin fections［J］. J Antimicrob Chemother, 2014,69: 463-470.
［11］Pascual A , Csajka C , Buclin T , et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: Population pharmacokinetics-based analysis of adult patients with invasive fungal infections［J］. Clin Infect Dis, 2012, 55(3):381-390.
［12］王柠柠,梁武,颜苗,等.在本院患者中建立伏立康唑群体药物代谢动力学模型的初步探索［J］. 中南药学,2015,13(11):1174-1177.
［13］Chen WY, Xie H, Liang FH, et al. Population pharmacokinetics in China: The dynamics of intravenous voriconazole in critically ill patients with pulmonary disease［J］. Biol Pharm Bull,2015,38:996-1004.
［14］Chen C, Yang T, Li X, et al. Population pharmacokinetics of voriconazole in Chinese patients with hematopoietic stem cell transplantation［J］. Eur J Drug Metab Pharmacokinet, 2019, https://doi.org/10.1007/s13318-019-00556-w.
［15］Han K, Capitano B, Bies R, et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients［J］. Antimicrob Agents Chemother, 2010, 54(10):4424-4431.
［16］Han K, Bies R, Johnson H, et al. Population pharmacokinetic evaluation with external validation and bayesian estimator of voriconazole in liver transplant recipients［J］. Clin Pharmacokinet,2011,50(3): 201-214.
［17］Li ZW, Peng FH, Yan M, et al. Impact of CYP2C19 genotype and liver function on voriconazole pharmacokinetics in renal transplant recipients［J］. Ther Drug Monit,2017,39(4):422-428.
［18］Lin XB, Li ZW, Yan M, et al. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients［J］. Brit J Clin Pharmacol,2018,84(7):1587-1597.
［19］李紫薇,颜苗,彭风华,等.伏立康唑在肾移植患者中的群体药动学研究［J］.中国医院药学杂志,2017,37(3):221-226.
［20］Christenson JT, Schmuziger M, Maurice J, et al. Postoperative visceral hypotension the common cause for gastrointestinal complications after cardiac surgery［J］. Thorac Cardiovasc Surg, 1994,42 (3): 152-159.
［21］Kennedy JM, Riji AM. Effects of surgery on the pharmacokinetic parameters of drugs［J］. Clin Pharmacokinet,1998,35 (4): 293-312.
［22］Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications［J］. Antimicrob Agents Chemother,2009,53:24-34.
［23］王晶晶,何瑾,王露婕,等.61例伏立康唑血药浓度结果分析［J］.中国医院药学杂志,2016, 36(9):770-773.

[1]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[2]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[3]	WANG Xin, WU Guodong, AN Ming, LI Gang, LIU Yang. Advances in venlafaxine-related PK-PD relationship and influencing factors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 788-795.
[4]	QIAN Jin, WANG Fengyan. Influence factors of serum NT-proBNP level in elderly patients with acute myocardial infarction after PCI and its influence on short-term prognosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 658-665.
[5]	HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
[6]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[7]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[8]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[9]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[10]	ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi. Interactions and clinical significance of gut microbiota and levothyroxine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314.
[11]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[12]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[13]	MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling. Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
[14]	DAI Jingyi, WANG Jingjing, ZHANG Jing, YU Jicheng, LI Nanyang, HUANG Zhiwei. Clinical application and research progress of inhaled methoxyflurane [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 808-813.
[15]	PAN Shu, WU Yijin, ZHANG Sasa, WANG Qihai, LUO Tingting, YIN Qin. Pharmacokinetics of methotrexate mediated by organic anion transporter 3 in adjuvant induced arthritis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 516-525.